How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

998 results for

Androgenic Alopecia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Health status, coping strategies, and alexithymia in subjects with androgenetic alopecia: a questionnaire study. (Abstract)

Health status, coping strategies, and alexithymia in subjects with androgenetic alopecia: a questionnaire study. Androgenic alopecia (AGA) is viewed as a relatively mild dermatologic condition; however, affected individuals feel that alopecia is a serious condition with major consequences in their life.The objective of this study was to assess the health status, the risk of anxiety/depression, the coping strategies, and alexithymia in subjects with AGA.Consecutive subjects referred (...) their alopecia than to the objective clinical rating. Avoidant coping strategies were selected more frequently by AGA subjects if they were GHQ-12 positive and had alexithymia. To have alexithymia modified all coping strategies in AGA female subjects but not in AGA male subjects. Physicians should be aware that the impact of AGA is not limited to symptoms, and should help people to deal with their emotional responses to alopecia, such as anger and worry, and their beliefs about the consequences

2013 American journal of clinical dermatology

162. Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients

Alopecia (female pattern hair loss) Exclusion Criteria: patients with alopecia areata or cicatricial alopecia pregnancy and breastfeeding have undergone any specific treatment in the last 06 months use of drugs with anti-androgenic properties patients with signs or symptoms of hyper-androgynism Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided (...) diagnosed with female pattern hair loss will undergo mesotherapy sessions weekly for ten weeks. One group will receive 0.5%/2ml minoxidil application and a control group will receive application of placebo (saline 0.9%). Biopsy of the scalp, trichogram and trichoscopy (Fotofinder) will be performed before and 08 weeks after treatment as a method objective evaluation of the response Condition or disease Intervention/treatment Phase Female Pattern Alopecia Drug: Minoxidil Drug: Saline Phase 3 Detailed

2012 Clinical Trials

163. The contribution of endogenous and exogenous factors to female alopecia: a study of identical twins. (Abstract)

(p = 0.048), and lack of exercise (p = 0.012) were associated with increased vertex hair loss. Higher testosterone levels were associated with increased temporal and vertex hair loss patterns (p < 0.039). Increased stress, increased smoking, having more children, and having a history of hypertension and cancer were all associated with increased hair thinning (p < 0.05).This study implicates several environmental risk factors in the pathophysiology of female alopecia. (...) The contribution of endogenous and exogenous factors to female alopecia: a study of identical twins. In this study, the authors investigated the potential contribution of environmental factors and testosterone levels on androgenic alopecia in women.Ninety-eight identical female twins were recruited from 2009 to 2011. Subjects were asked to complete a comprehensive questionnaire, provide a sputum sample for testosterone analysis, and pose for standardized digital photography. Frontal, temporal

2012 Plastic and reconstructive surgery

164. Age dependent associations between androgenetic alopecia and prostate cancer risk. Full Text available with Trip Pro

Age dependent associations between androgenetic alopecia and prostate cancer risk. Both prostate cancer and androgenetic alopecia are strongly age-related conditions that are considered to be androgen dependent, but studies of the relationship between them have yielded inconsistent results. We aimed to assess whether androgenetic alopecia at ages 20 and 40 years are associated with risk of prostate cancer.At a follow-up of the Melbourne Collaborative Cohort Study, men were asked to assess (...) their hair pattern at ages 20 and 40 years relative to eight categories in showcards. Cases were men notified to the Victorian Cancer Registry with prostate cancer diagnosed between cohort enrollment (1990-1994) and follow-up attendance (2003-2009). Flexible parametric survival models were used to estimate age-varying HRs and predicted cumulative probabilities of prostate cancer by androgenetic alopecia categories.Of 9,448 men that attended follow-up and provided data on androgenetic alopecia, we

2012 Cancer Epidemiology & Biomarkers and Prevention

165. This is a Phase 1, Open-label, and Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Efficacy of TAK-385 in Japanese Patients With Androgen Deprivation Treatment-naïve Nonmetastatic Prostate Cancer.

This is a Phase 1, Open-label, and Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Efficacy of TAK-385 in Japanese Patients With Androgen Deprivation Treatment-naïve Nonmetastatic Prostate Cancer. A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail (...) antiandrogen, non-steroidal androgen) for prostate cancer. Participants who have not undergone surgical castration. Participants with serum testosterone at screening greater than (>) 150 nanogram per deciliter (ng/dL). Participants meeting either of the following criteria for prostate-specific antigen (PSA) at screening. Untreated prostate cancer: PSA at screening > 4.0 nanogram per milliliter (ng/mL) Treated* prostate cancer: PSA at screening > 0.2 ng/mL. Participants who have undergone prostatectomy

2014 Clinical Trials

166. Topical Bimatoprost Effect on Androgen Dependent Hair Follicles

Responsible Party: Duke University ClinicalTrials.gov Identifier: Other Study ID Numbers: Pro00017573 First Posted: June 23, 2014 Results First Posted: August 20, 2014 Last Update Posted: September 5, 2014 Last Verified: July 2014 Keywords provided by Duke University: male pattern hair loss androgenetic alopecia bimatoprost Additional relevant MeSH terms: Layout table for MeSH terms Alopecia Alopecia Areata Hypotrichosis Hair Diseases Skin Diseases Pathological Conditions, Anatomical Androgens Bimatoprost (...) . Thirty-three subjects were consented and screened, 9 entered and 9 completed the study. Condition or disease Intervention/treatment Phase Male Pattern Hair Loss Androgenetic Alopecia Drug: Bimatoprost Drug: Placebo Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 33 participants Allocation: Randomized Intervention Model: Crossover Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose

2014 Clinical Trials

167. Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors

. If a patient declines to participate in voluntary exploratory research and/or genetic component of study, there will be no penalty or loss of benefit to the patient and he/she will not be excluded from other aspects of the study. Part A Dose Escalation Patients must have histological or cytological confirmation of a solid tumour of either locally advanced or metastatic castrate resistant prostate cancer (mCRPC), breast, bladder, ovarian, gastric or salivary duct carcinoma where an Androgen Receptor pathway (...) Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study

2014 Clinical Trials

168. Obliteration of Alopecia by Hair-Lifting: A New Concept and Technique Full Text available with Trip Pro

Obliteration of Alopecia by Hair-Lifting: A New Concept and Technique A new concept and technique of treatment of male-pattern alopecia are described. The concept is to remove, in serial stages, segments of skin that measure about 3 cm by 7 to 10 cm from the bald area of an alopecic scalp, and to raise the remaining hairy portion into the previously bald area.The technique consists of undermining the skin in the normal plane of cleavage between the galea and the sub-aponeurotic loose connective (...) for tonsure baldness in men and even in the skull-cap type of androgenic alopecia in women.

1977 Journal of the National Medical Association

169. New Treatment for Seborrheic Alopecia: The Ligature of the Arteries of the Scalp Full Text available with Trip Pro

New Treatment for Seborrheic Alopecia: The Ligature of the Arteries of the Scalp Bilateral ligature of the superficial temporal arteries and of the posterior auricular arteries is proposed as a treatment for seborrheic alopecia. The arterial circulatory dynamics are, thus, replaced by capillary circulatory dynamics. Hypoxia is produced which inhibits enzymatic systems and lessens nocuous action of androgen and lipid factors on the pilosebaceous effectors. The histologic study shows (...) that the production of sebum is greatly reduced and the condition of the hair follicle is strikingly improved.

1977 Journal of the National Medical Association

170. Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. Full Text available with Trip Pro

Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. Androgenetic alopecia affects both men and women. In men it produces male pattern hair loss with bitemporal recession and vertex baldness. In women it produces female pattern hair loss (FPHL) with diffuse alopecia over the mid-frontal scalp. FPHL occurs as a result of nonuniform hair follicle miniaturization within follicular units. Diffuse alopecia is produced by a reduction in the number of terminal fibres (...) per follicular unit. Baldness occurs only when all hairs within the follicular units are miniaturized and is a relatively late event in women. The concepts of follicular units and primary and secondary hair follicles within follicular units are well established in comparative mammalian studies, particularly in sheep. However, discovery of these structures in the human scalp hair and investigation of the changes in follicular unit anatomy during the development of androgenetic alopecia have

2011 British Journal of Dermatology

171. Androgen Excess (Treatment)

occur. [ ] Women using these methods can be reassured that these methods do not exacerbate hair growth, but they will not lower the androgen levels if they are elevated. Combining one of these local measures with systemic treatment might help achieve rapid response and better patient satisfaction. Next: Surgical Care Surgical removal is the standard therapy for ovarian and adrenal tumors that result in androgen excess. Surgery for PCOS is less commonly performed today, since adhesions routinely (...) tumors should be evaluated and treated by an obstetrician-gynecologist or a gynecologic oncologist. Previous Next: Diet In women who are obese, a modification of life style and weight loss are pivotal. Suppression of hair growth is unlikely without weight loss. [ ] A loss of 5-10% of body weight for obese women with PCOS in a 6-month period is enough to greatly improve hirsutism in most women. [ ] Previous Next: Activity Regular exercise and behavioral modification programs are essential for acute

2014 eMedicine.com

172. Androgen Excess (Overview)

vesicles, and the prostate. Postnatal females are not as sensitive as the fetus to androgens, which induce the growth of sexual hair, temporal balding, acne, clitoral growth, sebum production, and a deepening of the voice. Oral androgens decrease high-density lipoprotein (HDL) cholesterol and increase low-density lipoprotein (LDL) cholesterol. With androgen excess, the extent of these changes is dependent on the level of androgens in the blood. Androgen effects on various tissues and systems Androgens (...) antiandrogens; on the other hand, administration of testosterone in women with hypoactive sexual desire disorder results in improvements in libido and sexual function. [ , ] Bone Androgens have important roles in bone mineralization either directly or through aromatization to estrogen. Lower androgen concentrations have been associated with bone loss in various age groups. [ ] Breast Androgen receptors are present in mammary epithelial cells in addition to estrogen and progesterone receptors. The proposed

2014 eMedicine.com

173. Androgen Excess (Follow-up)

Metab . 1961 Nov. 21:1440-7. . Cela E, Robertson C, Rush K, Kousta E, White DM, Wilson H, et al. Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol . 2003 Nov. 149(5):439-42. . Kahana M, Grossman E, Feinstein A, Ronnen M, Cohen M, Millet MS. Skin tags: a cutaneous marker for diabetes mellitus. Acta Derm Venereol . 1987. 67(2):175-7. . Franks S. Polycystic ovary syndrome. N Engl J Med . 1995 Sep 28. 333(13):853-61. . Azziz R, Carmina E, Dewailly D, Diamanti (...) Androgen Excess (Follow-up) Androgen Excess Follow-up: Further Outpatient Care, Prognosis Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjczMTUzLWZvbGxvd3Vw processing > Androgen Excess Follow-up Updated: Mar 14

2014 eMedicine.com

174. Androgen Excess (Diagnosis)

vesicles, and the prostate. Postnatal females are not as sensitive as the fetus to androgens, which induce the growth of sexual hair, temporal balding, acne, clitoral growth, sebum production, and a deepening of the voice. Oral androgens decrease high-density lipoprotein (HDL) cholesterol and increase low-density lipoprotein (LDL) cholesterol. With androgen excess, the extent of these changes is dependent on the level of androgens in the blood. Androgen effects on various tissues and systems Androgens (...) antiandrogens; on the other hand, administration of testosterone in women with hypoactive sexual desire disorder results in improvements in libido and sexual function. [ , ] Bone Androgens have important roles in bone mineralization either directly or through aromatization to estrogen. Lower androgen concentrations have been associated with bone loss in various age groups. [ ] Breast Androgen receptors are present in mammary epithelial cells in addition to estrogen and progesterone receptors. The proposed

2014 eMedicine.com

175. Androgen Insensitivity Syndrome (Diagnosis)

syndrome, the standard of care is an orchidectomy to prevent possible malignant degeneration of the testes. [ ] Next: Pathophysiology The basic etiology of androgen insensitivity syndrome is a loss-of-function mutation in the androgen receptor ( AR ) gene. This AR gene has been localized to the long arm of the X chromosome (ie, Xq11-13). Over 1,000 such mutations have been described, including complete and partial gene deletions, point mutations, and small insertions/deletions. These mutations can (...) cause a variety of functional defects, ranging from a complete loss of receptors on the cell surface because of incomplete protein synthesis to alterations in substrate binding affinity. Altered substrate binding affinity causes a signal transmission loss, despite normal cell surface receptor numbers. While the genotypes causing complete androgen insensitivity syndrome are fairly consistent in phenotypic presentation, the genotype/phenotype relationships for the mutations causing partial androgen

2014 eMedicine Pediatrics

176. Androgen Insensitivity Syndrome (Overview)

syndrome, the standard of care is an orchidectomy to prevent possible malignant degeneration of the testes. [ ] Next: Pathophysiology The basic etiology of androgen insensitivity syndrome is a loss-of-function mutation in the androgen receptor ( AR ) gene. This AR gene has been localized to the long arm of the X chromosome (ie, Xq11-13). Over 1,000 such mutations have been described, including complete and partial gene deletions, point mutations, and small insertions/deletions. These mutations can (...) cause a variety of functional defects, ranging from a complete loss of receptors on the cell surface because of incomplete protein synthesis to alterations in substrate binding affinity. Altered substrate binding affinity causes a signal transmission loss, despite normal cell surface receptor numbers. While the genotypes causing complete androgen insensitivity syndrome are fairly consistent in phenotypic presentation, the genotype/phenotype relationships for the mutations causing partial androgen

2014 eMedicine Pediatrics

177. Molecular basis of androgenetic alopecia: From androgen to paracrine mediators through dermal papilla. (Abstract)

Molecular basis of androgenetic alopecia: From androgen to paracrine mediators through dermal papilla. Androgenetic alopecia (AGA) is characterized by vellus transformation of scalp hairs, corresponding to hair follicle miniaturization during repeated hair cycles with shortened anagen phase. This phenomenon is mediated mainly by androgen. Then, the multi-step molecular pathway of androgen can be involved in the pathogenesis of AGA. The expression of type II 5α-reductase is higher in dermal (...) papilla cells from AGA and beard than those from other sites. On the other hand, type I 5α-reductase expression is relatively low. Next, hormone binding assays and RT-PCR demonstrated that androgen receptor (AR) expression is significantly higher in bald dermal papilla cells than non-bald cells. Additionally, AR coactivator Hic-5/ARA55 is highly expressed in dermal papilla cells of hair follicles from androgen-sensitive sites such as AGA and beard. Collectively, the enhanced expression of type II 5α

2011 Journal of dermatological science

178. Hyposecretion of the Adrenal Androgen Dehydroepiandrosterone Sulfate (DHEA-S) in the Majority of the Alopecia Areata Patients: Is it a Primitive and Pathogenic Perturbation of Hypothalamic-Pituitary-Adrenal Axis? Full Text available with Trip Pro

Hyposecretion of the Adrenal Androgen Dehydroepiandrosterone Sulfate (DHEA-S) in the Majority of the Alopecia Areata Patients: Is it a Primitive and Pathogenic Perturbation of Hypothalamic-Pituitary-Adrenal Axis? 21769240 2011 11 10 2018 11 13 0974-9241 3 1 2011 Jan International journal of trichology Int J Trichology Hyposecretion of the Adrenal Androgen Dehydroepiandrosterone Sulfate (DHEA-S) in the Majority of the Alopecia Areata Patients: Is it a Primitive and Pathogenic Perturbation

2011 International journal of trichology

179. Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia

, Layout table for eligibility information Ages Eligible for Study: 18 Years to 49 Years (Adult) Sexes Eligible for Study: Male Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss for at least 1 year Willingness to have micro-dot-tattoo applied to scalp Willingness to maintain same hair style, length and hair color during study Exclusion Criteria: Drug or alcohol abuse within 12 months HIV positive Received hair (...) Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2011 Clinical Trials

180. Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. (Abstract)

Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. When studies of postmenopausal women with hair loss failed to reveal a response to the 5 alpha reductase inhibitor, finasteride, researchers began to question the existence of androgenetic alopecia in women and renamed the clinical entity female pattern hair loss. However, recently published reports of finasteride response in some women (...) with hair loss suggest that an androgenic mechanism is mediating response in this group. Variant repeat nucleotide sequences in exon 1 of the androgen receptor (AR) gene have been shown to determine androgen sensitivity in a variety of androgenic conditions in men and women. In an effort to identify whether this AR variant may help determine which women are likely to respond to finasteride therapy, a pilot study was undertaken. In our 6-month pilot of 13 patients, women with greater androgen sensitivity

2011 Dermatologic therapy Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>